Human Cell Study on Myelin Microphysiological Systems in MS
In a preclinical laboratory study, a human myelin microphysiological system was used to demonstrate that autologous T cells from MS patients induced significantly greater demyelination compared to T cells from healthy donors. The study also observed changes in immune cell profiles, particularly among proinflammatory T-cell subsets.
- Tags
- #Other
- Most relevant to
- —
Why it matters
These findings indicate that the myelin MPS platform can effectively model MS pathology and treatment responses, potentially aiding in the development of personalized treatment strategies. However, the results are not indicative of clinical efficacy in human patients.
What this does not prove
The study does not establish the efficacy of treatments in a clinical setting, and results from this laboratory model may not fully translate to actual human patients.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Laboratory
- Participants / samples
- 96 · models generated
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- All
- Publication date
- 2026-09-18
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Other
Original sources
- Primary evidenceEngineering human myelin microphysiological systems for testing patient treatment response in multiple sclerosis. ↗DOI: 10.64898/2026.09.12.750449
Supporting passages (13)
study phaseThus, the myelin MPS platform provides a scalable, human pathophysiology-relevant platform for functional phenotyping and individualized treatment-response evaluation in MS.
study designHere, we report a human myelin microphysiological system (myelin MPS) platform that recaptures disease phenotype and treatment response for testing patient treatment response.
subjectsUsing this myelin MPS platform, autologous T cells and monocytes from MS patients induced substantially greater demyelination than those from healthy donors, accompanied by expansion of proinflammatory T-cell subsets and increased myelin uptake by monocytes/macrophages after coculture with these healthy myelinating neural tissues.
sample size96 myelin MPS models can be generated within a conventional well plate.
sample size basis96 myelin MPS models can be generated within a conventional well plate.
research categoriesThus, the myelin MPS platform provides a scalable, human pathophysiology-relevant platform for functional phenotyping and individualized treatment-response evaluation in MS.
relevant ms typesThus, the myelin MPS platform provides a scalable, human pathophysiology-relevant platform for functional phenotyping and individualized treatment-response evaluation in MS.
publication date2026-09-18
interventionprednisone, glatiramer acetate, interferon β-1a, or dimethyl fumarate.
comparatorUsing this myelin MPS platform, autologous T cells and monocytes from MS patients induced substantially greater demyelination than those from healthy donors, accompanied by expansion of proinflammatory T-cell subsets and increased myelin uptake by monocytes/macrophages after coculture with these healthy myelinating neural tissues.
primary endpointtesting patient treatment response.
findingsUsing this myelin MPS platform, autologous T cells and monocytes from MS patients induced substantially greater demyelination than those from healthy donors, accompanied by expansion of proinflammatory T-cell subsets and increased myelin uptake by monocytes/macrophages after coculture with these healthy myelinating neural tissues.
limitationsTitle: Engineering human myelin microphysiological systems for testing patient treatment response in multiple sclerosis.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.